# Project 2: Discovery of novel C. difficile antigens using genetic and biochemical approaches

> **NIH NIH U19** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2024 · $332,857

## Abstract

PROJECT 2 SUMMARY
Clostridioides difficile is a spore-forming anaerobic bacterium that is the number one cause of hospital-
acquired diarrhea and pseudomembranous colitis in the United States. The incidence of C. difficile infection
(CDI) has been rapidly rising since the 1990s and is linked to increased antibiotic use. The emergence of new
highly virulent strains over the past two decades has contributed to CDI cases spreading from elderly and
immunocompromised populations in healthcare settings, to community-acquired and zoonotic infections among
healthy adults. Although CDI is a toxin-mediated disease, vaccine trials targeting toxoids have failed to produce
effective vaccines.There is a concern that even the most effective anti-toxin strategy will not prevent the intestinal
colonization of C. difficile. Additional bacterial vaccine targets that promote immune system mediated clearance
of both vegetative bacteria and spores are needed. A strong IgA/IgG response to a conserved antigen found on
the C. difficile surface will provide the necessary target to promote a bactericidal immune response and/or by
blocking bacterial adherence and colonization within the colon. This proposal presents two aims to identify
relevant antigens and a third aim to test the new antigens for protection in a mouse immunization model. The
first approach is to use a genetic selection in a murine model to identify antigens that are selectively targeted by
the adaptive immune response. The second approach will use two biochemical strategies that will both leverage
human clinical samples from recovered CDI patients. The first of these biochemical approaches will use a
recently developed promiscuous biotin ligase to enzymatically biotinylate C. difficile antigens bound to antibodies
from the human sera. The second biochemical approach will sort patient B-cells against fluorescently labeled
C. difficile to identify antibodies that target surface proteins on C. difficile. These mABs will be characterized for
binding to C. difficile and used for antigen discovery. In both biochemical approaches we will prioritize antigens
associated with IgA class antibodies. In the third aim of this project, antigens will be assessed and prioritized.
The most promising antigens, based on multiple considerations including conservation across isolates, strength
of the identifying signals, and predicted cellular location, will be expressed and purified by Core 2. These antigens
will be evaluated for binding patient sera samples by ELISA and the most promising candidates will be evaluated
(in collaboration with Core 4) for immunogenicity and their ability to induce a protective immune response in our
pre-clinical murine vaccine mode.

## Key facts

- **NIH application ID:** 10800738
- **Project number:** 5U19AI174999-02
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** Eric P Skaar
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $332,857
- **Award type:** 5
- **Project period:** 2023-03-03 → 2028-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10800738

## Citation

> US National Institutes of Health, RePORTER application 10800738, Project 2: Discovery of novel C. difficile antigens using genetic and biochemical approaches (5U19AI174999-02). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10800738. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*